238 related articles for article (PubMed ID: 16359541)
1. Evaluation of biological potential of smooth muscle tumours.
Miettinen M; Fetsch JF
Histopathology; 2006 Jan; 48(1):97-105. PubMed ID: 16359541
[TBL] [Abstract][Full Text] [Related]
2. True smooth muscle tumors of the small intestine: a clinicopathologic, immunhistochemical, and molecular genetic study of 25 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Mar; 33(3):430-6. PubMed ID: 18971781
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
4. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
5. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
6. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
9. Sinonasal smooth muscle cell tumors: a clinicopathologic and immunohistochemical analysis of 12 cases with emphasis on the low-grade end of the spectrum.
Huang HY; Antonescu CR
Arch Pathol Lab Med; 2003 Mar; 127(3):297-304. PubMed ID: 12653572
[TBL] [Abstract][Full Text] [Related]
10. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
Ip PP; Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
[TBL] [Abstract][Full Text] [Related]
11. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
Patil DT; Laskin WB; Fetsch JF; Miettinen M
Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
[TBL] [Abstract][Full Text] [Related]
12. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
13. Predictors of malignant behaviour in gastrointestinal stromal tumours: a clinicopathological study of 34 cases.
Abdulkader I; Cameselle-Teijeiro J; Gude F; Fraga M; Varela-Durán J; Barreiro F; Forteza J
Eur J Surg; 2002; 168(5):288-96. PubMed ID: 12375611
[TBL] [Abstract][Full Text] [Related]
14. Proliferation, ploidy and prognosis in uterine smooth muscle tumours.
Jeffers MD; Oakes SJ; Richmond JA; Macaulay EM
Histopathology; 1996 Sep; 29(3):217-23. PubMed ID: 8884349
[TBL] [Abstract][Full Text] [Related]
15. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
16. Caveolin expression is common among benign and malignant smooth muscle and adipocyte neoplasms.
Bayer-Garner I; Morgan M; Smoller BR
Mod Pathol; 2002 Jan; 15(1):1-5. PubMed ID: 11796834
[TBL] [Abstract][Full Text] [Related]
17. Criteria for malignancy in nonvisceral smooth muscle tumors.
Hornick JL; Fletcher CD
Ann Diagn Pathol; 2003 Feb; 7(1):60-6. PubMed ID: 12616476
[TBL] [Abstract][Full Text] [Related]
18. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
19. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.
Giuntoli RL; Gostout BS; DiMarco CS; Metzinger DS; Keeney GL
J Reprod Med; 2007 Nov; 52(11):1001-10. PubMed ID: 18161397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
